Your browser doesn't support javascript.
loading
NOTCH1 signaling during CD4+ T-cell activation alters transcription factor networks and enhances antigen responsiveness.
Wilkens, Alec B; Fulton, Elena C; Pont, Margot J; Cole, Gabriel O; Leung, Isabel; Stull, Sylvia M; Hart, Matthew R; Bernstein, Irwin D; Furlan, Scott N; Riddell, Stanley R.
Afiliación
  • Wilkens AB; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
  • Fulton EC; Molecular and Cellular Biology, University of Washington, Seattle, WA.
  • Pont MJ; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
  • Cole GO; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
  • Leung I; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
  • Stull SM; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
  • Hart MR; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
  • Bernstein ID; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
  • Furlan SN; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
  • Riddell SR; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
Blood ; 140(21): 2261-2275, 2022 11 24.
Article en En | MEDLINE | ID: mdl-35605191
ABSTRACT
Adoptive transfer of T cells expressing chimeric antigen receptors (CAR-T) effectively treats refractory hematologic malignancies in a subset of patients but can be limited by poor T-cell expansion and persistence in vivo. Less differentiated T-cell states correlate with the capacity of CAR-T to proliferate and mediate antitumor responses, and interventions that limit tumor-specific T-cell differentiation during ex vivo manufacturing enhance efficacy. NOTCH signaling is involved in fate decisions across diverse cell lineages and in memory CD8+ T cells was reported to upregulate the transcription factor FOXM1, attenuate differentiation, and enhance proliferation and antitumor efficacy in vivo. Here, we used a cell-free culture system to provide an agonistic NOTCH1 signal during naïve CD4+ T-cell activation and CAR-T production and studied the effects on differentiation, transcription factor expression, cytokine production, and responses to tumor. NOTCH1 agonism efficiently induced a stem cell memory phenotype in CAR-T derived from naïve but not memory CD4+ T cells and upregulated expression of AhR and c-MAF, driving heightened production of interleukin-22, interleukin-10, and granzyme B. NOTCH1-agonized CD4+ CAR-T demonstrated enhanced antigen responsiveness and proliferated to strikingly higher frequencies in mice bearing human lymphoma xenografts. NOTCH1-agonized CD4+ CAR-T also provided superior help to cotransferred CD8+ CAR-T, driving improved expansion and curative antitumor responses in vivo at low CAR-T doses. Our data expand the mechanisms by which NOTCH can shape CD4+ T-cell behavior and demonstrate that activating NOTCH1 signaling during genetic modification ex vivo is a potential strategy for enhancing the function of T cells engineered with tumor-targeting receptors.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Receptores Quiméricos de Antígenos / Linfoma Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Blood Año: 2022 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Receptores Quiméricos de Antígenos / Linfoma Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Blood Año: 2022 Tipo del documento: Article